Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexeo Therapeutics (LXEO) Preferred Stock Liabilities (2022 - 2023)

Lexeo Therapeutics' Preferred Stock Liabilities history spans 2 years, with the latest figure at $99.8 million for Q3 2023.

  • On a quarterly basis, Preferred Stock Liabilities fell 46.08% to $99.8 million in Q3 2023 year-over-year; TTM through Sep 2023 was $99.8 million, a 46.08% decrease, with the full-year FY2022 number at $185.0 million, changed N/A from a year prior.
  • Preferred Stock Liabilities hit $99.8 million in Q3 2023 for Lexeo Therapeutics, down from $185.0 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for LXEO hit a ceiling of $185.0 million in Q3 2022 and a floor of $99.8 million in Q3 2023.